• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.

    9/12/25 6:09:33 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYCC alert in real time by email
    425 1 form425.htm 425

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    September 12, 2025

    Date of Report (date of earliest event reported)

     

     Cyclacel Pharmaceuticals, Inc

    Bio Green Med Solution, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   0-50626   91-1707622
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification Number)

     

    Level 10, Tower 11, Avenue 5, No. 8

    Jalan Kerinchi, Kuala Lumpur, Malaysia 59200

    (Address of principal executive offices) (Zip code)

     

    (908) 517-7330

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   BGMS   The Nasdaq Capital Market
    Preferred Stock, $0.001 par value   BGMSP   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.01. Completion of Acquisition or Disposition of Assets.

     

    On September 12, 2025, Bio Green Med Solution, Inc. (f.k.a. Cyclacel Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), completed the acquisition of FITTERS Sdn. Bhd. (“Fitters”), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company (“Fitters Parent”), pursuant to a share exchange agreement dated May 6, 2025, as amended (the “Exchange Agreement”) among the Company, Fitters and Fitters Parent. Under the terms of the Exchange Agreement, the parties effected a voluntary share exchange transaction (the “Transaction”) whereby Fitters Parent exchanged all of its ownership interest in Fitters representing 100% of all of the issued and outstanding capital shares of Fitters, for 699,158 shares of common stock, par value $0.001, of the Company. Following the closing of the Transaction, Fitters became a wholly-owned subsidiary of the Company and Datuk Dr. Doris Wong Sing Ee, our Chief Executive Officer and Executive Director was appointed as a director of Fitters and all of its subsidiaries.

     

    Fitters specializes in the supply and trading of protective and fire safety equipment. It is headquartered in Kuala Lumpur, Malaysia, and provides a wide range of fire safety products, including fire extinguishers, foam system, fire-resistant doors, personal protective equipment, and fire safety apparel. Fitters’ mission is to deliver high-quality, certified safety solutions that enhance protection across commercial, industrial, healthcare, and residential sectors. Its focus on trading and distribution positions it as a key player in Malaysia’s fire safety market, with a reputation for reliability and compliance with stringent regulatory standards. Over the past four decades, Fitters has expanded its product portfolio to include advanced fire-fighting equipment, foam system, personal protective equipment, and safety apparel, establishing a strong presence in the industry.

     

    The material provisions of the Exchange Agreement are described in the Company’s definitive proxy statement/prospectus filed on Form S-4 with the U.S. Securities and Exchange Commission and declared effective on July 25, 2025 (the “Proxy Statement/Prospectus”) in the section entitled “The Exchange Agreement” beginning on page 94 and are incorporated herein by reference.

     

    All of the proposals included in the Proxy Statement/Prospectus were approved by the Company’s stockholders at a special meeting of stockholders held on September 4, 2025 (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved, among other matters, amendments to the amended and restated certificate of incorporation of the Company to change the corporate name of the Company to “Bio Green Med Solution, Inc.,” permit actions by stockholders by written consent and ratify all prior action by stockholder written consent, and opt out of the business combination provisions of Section 203 of the DGCL. To effect the amendments, the Company filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), effective September 12, 2025.

     

    The Company’s Common Stock and 6% convertible preferred stock, par value $0.001 (the “Preferred Stock”), commenced trading at the open of trading on September 12, 2025, under a new symbol “BGMS” and “BGMSP,” respectively. The CUSIP number and par value per share of the Company’s Common Stock and Preferred Stock will remain unchanged.

     

    The Company is now a diversified company engaged in both the fire protection and biopharmaceutical industries. Building on its legacy in pharmaceutical research and development, the Company has expanded its business portfolio through the integration of Fitters. The Company will remain headquartered in Malaysia, and is focused on advancing opportunities across these distinct sectors while maintaining its commitment to driving long-term value creation for its stockholders.

     

    The foregoing description of the Exchange Agreement and Certificate of Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the complete text of the Exchange Agreement, as amended, copies of which are attached hereto as Exhibits 2.1 and 2.2, and the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1, and all of which are incorporated herein by reference.

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    2

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    Amendment to Amended and Restated Certificate of Incorporation

     

    The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 7.01. Regulation FD Disclosure

     

    On September 12, 2025, the Company issued a press release announcing the completion of the Transaction. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information set forth in Item 7.01 of this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (a)Financial Statements of the Business Acquired

     

    The unaudited financial statements of Fitters for the three months ended June 30, 2025 and 2024 and the related notes thereto are attached hereto as Exhibit 99.2 and are incorporated herein by reference.

     

    (b)Pro Forma Financial Information

     

    The unaudited pro forma condensed combined financial information of the Company and Fitters as of June 30, 2025, and for the three months ended June 30, 2025, and for the year ended December 31, 2024, and the related notes thereto are attached hereto as Exhibit 99.3 and are incorporated herein by reference.

     

    (d) Exhibits.

     

    Exhibit No.   Exhibit
         
    2.1   Exchange Agreement dated May 6, 2025 (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities Exchange Commission on May 6, 2025)
    2.2   Amendment No. 1 to Exchange Agreement dated July 7, 2025 (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities Exchange Commission on July 7, 2025)
    3.1   Certificate of Amendment to Amended and Restated Certificate of Incorporation
    10.1#   Trademark License Agreement dated September 12, 2025 between FITTERS Diversified Berhad and FITTERS Sdn. Bhd.
    99.1   Press Release dated September 12, 2025
    99.2   Unaudited Financial Statements of Fitters for the three months ended June 30, 2025 and 2024.
    99.3   Unaudited Pro Forma Financial Statements of the Company and Fitters as of June 30, 2025, and for the three months ended June 30, 2025, and for the year ended December 31, 2024
    104   Cover Page Interactive Data File (embedded within the XBRL document)

     

    #

      Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Regulation S-K, Item (601)(b)(10).

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: September 12, 2025 Bio Green Med Solution, Inc.
         
      By: /s/ Datuk Dr. Doris Wong Sing Ee
      Name: Datuk Dr. Doris Wong Sing Ee
      Title: Chief Executive Officer and Executive Director

     

    4

     

    Get the next $CYCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYCC

    DatePrice TargetRatingAnalyst
    7/18/2022$17.00Outperform
    Oppenheimer
    More analyst ratings

    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

    KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of t

    9/12/25 6:00:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

             - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, "Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker" in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BT

    8/4/25 6:50:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Cyclacel Pharma with a new price target

    Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00

    7/18/22 9:13:15 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Cyclacel Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00

    4/30/21 6:36:41 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    SEC Filings

    View All

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Bio Green Med Solution, Inc. (0001130166) (Filer)

    9/16/25 4:05:31 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.

    425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    9/12/25 6:09:33 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)

    9/12/25 6:07:02 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fitters Diversified Berhad claimed ownership of 699,158 shares (SEC Form 3)

    3 - Bio Green Med Solution, Inc. (0001130166) (Issuer)

    9/16/25 3:31:42 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Kua Khai Loon sold $133,569 worth of shares (19,054 units at $7.01), decreasing direct ownership by 5% to 385,411 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/10/25 3:09:51 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ong Yee Lung acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/4/25 4:00:15 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rombotis Spiro George bought $20,122 worth of shares (6,070 units at $3.31), increasing direct ownership by 10% to 68,658 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:23 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mcbarron Paul bought $6,252 worth of shares (1,886 units at $3.31), increasing direct ownership by 6% to 33,378 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:25 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company")), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. "As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-owned subsidiary that is currently in liquidation," said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer

    4/2/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

    BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts

    1/30/24 9:15:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

    – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar

    1/11/21 7:46:19 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.

    SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 3:27:04 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    2/14/24 4:31:09 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Financials

    Live finance-specific insights

    View All

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. "As part of the Company's efforts to reduce operating costs it has determined to focus on the development of the plogosertib ("plogo") clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to plogo from Cyclacel Limited for approximately $0.3 million in cash, to allow us to continue our efforts on developing an alternative salt, oral formulation of

    5/15/25 12:50:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. "We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), in Barcelona, Spain. The patients were enrolled in

    11/12/24 4:45:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care